Evaluation of the In Vitro Cytotoxic Activity of Ursolic Acid PLGA Nanoparticles against Pancreatic Ductal Adenocarcinoma Cell Lines.
PLGA
nanocarriers
nanoparticles
naturally derived compounds
pancreatic cancer
terpenoids
ursolic acid
Journal
Materials (Basel, Switzerland)
ISSN: 1996-1944
Titre abrégé: Materials (Basel)
Pays: Switzerland
ID NLM: 101555929
Informations de publication
Date de publication:
29 Aug 2021
29 Aug 2021
Historique:
received:
20
07
2021
revised:
24
08
2021
accepted:
25
08
2021
entrez:
10
9
2021
pubmed:
11
9
2021
medline:
11
9
2021
Statut:
epublish
Résumé
Among all the types of cancer, Pancreatic Ductal Adenocarcinoma remains one of the deadliest and hardest to fight and there is a critical unmet need for new drugs and therapies for its treatment. Naturally derived compounds, such as pentacyclic triterpenoids, have gathered attention because of their high cytotoxic potential towards pancreatic cancer cells, with a wide biological activity spectrum, with ursolic acid (UA) being one of the most interesting. However, due to its minimal water solubility, it is necessary to prepare a nanocarrier vehicle to aid in the delivery of this compound. Poly(lactic-
Identifiants
pubmed: 34501007
pii: ma14174917
doi: 10.3390/ma14174917
pmc: PMC8434451
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Semin Cancer Biol. 2017 Jun;44:153-169
pubmed: 28366542
Mater Sci Eng C Mater Biol Appl. 2019 May;98:764-771
pubmed: 30813082
Eur J Med Chem. 2019 Aug 15;176:268-291
pubmed: 31103904
Oncol Rep. 2012 Aug;28(2):501-10
pubmed: 22641480
Int J Oncol. 2017 Aug;51(2):555-562
pubmed: 28714512
Ther Adv Med Oncol. 2019 May 19;11:1758835919850367
pubmed: 31205510
Cancer Invest. 2009 Aug;27(7):723-33
pubmed: 19440893
Eur J Pharm Biopharm. 2013 Nov;85(3 Pt A):427-43
pubmed: 23872180
Cell Signal. 2009 Nov;21(11):1541-7
pubmed: 19298854
Molecules. 2019 May 26;24(10):
pubmed: 31130671
World J Oncol. 2019 Feb;10(1):10-27
pubmed: 30834048
J Nutr. 1999 Mar;129(3):775S-778S
pubmed: 10082788
J Zhejiang Univ Sci B. 2009 Sep;10(9):668-74
pubmed: 19735099
Pharm Res. 2016 Nov;33(11):2691-703
pubmed: 27431865
Oncotarget. 2017 Aug 2;8(38):64129-64142
pubmed: 28969057
Front Bioeng Biotechnol. 2020 Feb 11;8:48
pubmed: 32117928
Oncol Lett. 2019 Jun;17(6):4761-4767
pubmed: 31186681
J Control Release. 2010 May 10;143(3):374-82
pubmed: 20109508
Biochim Biophys Acta. 2016 Apr;1865(2):123-32
pubmed: 26794394
Atherosclerosis. 2011 Dec;219(2):402-8
pubmed: 21703625
Eur J Cancer. 2018 Nov;103:356-387
pubmed: 30100160
AAPS PharmSciTech. 2010 Sep;11(3):1456-65
pubmed: 20842542
Int Immunopharmacol. 2008 Jul;8(7):974-81
pubmed: 18486908
Chem Pharm Bull (Tokyo). 2007 Feb;55(2):159-222
pubmed: 17268091
Mater Sci Eng C Mater Biol Appl. 2017 Feb 1;71:1231-1240
pubmed: 27987679
Biomed Pharmacother. 2018 Dec;108:752-756
pubmed: 30248543
Results Pharma Sci. 2012;2:79-85
pubmed: 23316451
Cancer Res. 2000 May 1;60(9):2399-404
pubmed: 10811116
Crit Rev Ther Drug Carrier Syst. 2013;30(3):257-76
pubmed: 23614648
Molecules. 2019 Jul 29;24(15):
pubmed: 31362424
J Immunol Methods. 1983 Dec 16;65(1-2):55-63
pubmed: 6606682
Cancer Res. 1996 May 15;56(10):2281-4
pubmed: 8625299
Oncotarget. 2016 Mar 15;7(11):13182-96
pubmed: 26909608
Mater Sci Eng C Mater Biol Appl. 2015 Aug;53:196-203
pubmed: 26042707
Heliyon. 2019 May 24;5(5):e01769
pubmed: 31193530
Polymers (Basel). 2011 Sep 1;3(3):1377-1397
pubmed: 22577513
Acta Histochem. 2016 Apr;118(3):305-16
pubmed: 26868366
Cancer Res. 2014 Jun 1;74(11):2913-21
pubmed: 24840647
Saudi Pharm J. 2014 Jul;22(3):219-22
pubmed: 25061407
Front Chem. 2020 Dec 09;8:626468
pubmed: 33363121
Front Pharmacol. 2018 Nov 02;9:1260
pubmed: 30450050
Int J Nanomedicine. 2017 Oct 05;12:7291-7309
pubmed: 29042776
Curr Drug Targets. 2010 Jun;11(6):733-44
pubmed: 20298150
Cancer Res. 2003 Aug 1;63(15):4375-83
pubmed: 12907607
J Hematol Oncol. 2017 Jan 7;10(1):10
pubmed: 28061797
Altern Med Rev. 2010 Sep;15(3):264-72
pubmed: 21155627
Lancet Oncol. 2016 Jun;17(6):801-810
pubmed: 27160474
Phytochemistry. 2009 Oct-Nov;70(15-16):1621-37
pubmed: 19793600
Mol Pharm. 2019 Jul 1;16(7):2858-2871
pubmed: 31136710
Mol Nutr Food Res. 2010 Sep;54(9):1285-95
pubmed: 20352621
SAGE Open Med. 2014 Sep 02;2:2050312114546924
pubmed: 26770737
Oncol Lett. 2016 Oct;12(4):2880-2885
pubmed: 27698874
BMC Cancer. 2019 Jan 8;19(1):28
pubmed: 30621630
Biomed Res Int. 2013;2013:467147
pubmed: 23984367
Nanomedicine. 2015 Apr;11(3):521-30
pubmed: 25659643
Biomacromolecules. 2018 Jul 9;19(7):3030-3039
pubmed: 29883544
Acta Pharmacol Sin. 2004 Apr;25(4):480-4
pubmed: 15066217
Mol Pharm. 2020 Dec 7;17(12):4443-4462
pubmed: 32926628
Chem Biol Interact. 2014 Jul 25;218:28-41
pubmed: 24802810
Front Oncol. 2019 Nov 08;9:1153
pubmed: 31781485
Br J Clin Pharmacol. 2013 Mar;75(3):588-602
pubmed: 22897361
World J Gastrointest Oncol. 2020 Feb 15;12(2):182-194
pubmed: 32104549
Anticancer Drugs. 2009 Nov;20(10):880-92
pubmed: 19745720
SAGE Open Med. 2013 Nov 23;1:2050312113513759
pubmed: 26770691